Latest Breaking News On - தேவா மருந்துகள் யூரோப் - Page 1 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate) April 8, 2021 GMT AMSTERDAM (BUSINESS WIRE) Apr 8, 2021 Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK. Introducing Seffalair Spiromax and BroPair Spiromax The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma. Since the launch of DuoResp® Spiromax® (budeson

United kingdomSeffalair spiromaxBropair spiromaxPaul blonkFiona cohenTeva pharmaceuticals europeTeva pharmaceutical industries ltdPharmaceuticals europeTeva respiratoryTeva pharmaceutical industriesBusiness wireஒன்றுபட்டது கிஂக்டம்பியோனா கோஹன்தேவா மருந்துகள் யூரோப்தேவா மருந்து தொழில்கள் லிமிடெட்மருந்துகள் யூரோப்